Skip to main content

7 Result(s)

within J Jassem Remove this filter Cancer Research Remove this filter

and

  1. Article

    Open Access

    Prognostic value of microRNA expression in operable non-small cell lung cancer patients

    About 50% of non-small cell lung cancer (NSCLC) patients develop distant metastases following pulmonary resection. Currently, there are no reliable factors allowing for individual selection of high-risk patien...

    M Skrzypski, P Czapiewski, K Goryca, E Jassem, L Wyrwicz… in British Journal of Cancer (2014)

    Download PDF (438 KB) View Article

  2. Article

    Open Access

    Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

    To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC).

    G Minuti, F Cappuzzo, R Duchnowska, J Jassem, A Fabi… in British Journal of Cancer (2012)

    Download PDF (370 KB) View Article

  3. No Access

    Article

    Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression

    Purpose: The aim of this study was to assess the prognostic relevance of apoptotic index (AI), considered alone or together with expression of several proteins controlling G1 check point ...

    D. Dworakowska, E. Jassem, J. Jassem… in Journal of Cancer Research and Clinical On… (2005)

  4. Article

    Open Access

    A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

    A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5...

    E Senkus-Konefka, R Dziadziuszko, E Bednaruk-Młyński… in British Journal of Cancer (2005)

    Download PDF (286 KB) View Article

  5. No Access

    Article

    Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer

    The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine...

    M Bontenbal, M Andersson, J Wildiers, G Cocconi, J Jassem… in British Journal of Cancer (1998)

  6. Article

    Post-operative radiotherapy in non-small-cell lung cancer: more questions than answers

    H Bartelink, J Jassem in British Journal of Cancer (1996)

    Download PDF (213 KB)

  7. No Access

    Article

    Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study

    Between April 1986 and May 1989 a multicéntre study was conducted to evaluate the efficacy of a 4-h intravenous infusion of 1000 mg/m2 5-fluorouracil (5-FU) followed by a 1-h infusion of 25 mg/m2 cisplatin (CDDP)...

    J. Jassem, F. Gyergvay, S. Kerpel-Fronius… in Cancer Chemotherapy and Pharmacology (1993)